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Abstract: Macrophages are implicated in the pathogenesis of abdominal aortic aneurysm (AAA).
This study examined the environmentally conditioned responses of AAA macrophages to
inflammatory stimuli. Plasma- and blood-derived monocytes were separated from the whole
blood of patients with AAA (30–45 mm diameter; n = 33) and sex-matched control participants
(n = 44). Increased concentrations of pro-inflammatory and pro-oxidant biomarkers were detected in
the plasma of AAA patients, consistent with systemic inflammation and oxidative stress. However,
in monocyte-derived macrophages, a suppressed cytokine response was observed in AAA compared
to the control following stimulation with lipopolysaccharide (LPS) (tumor necrosis factor alpha
(TNF-α) 26.9 ± 3.3 vs. 15.5 ± 3.2 ng/mL, p < 0.05; IL-6 3.2 ± 0.6 vs. 1.4 ± 0.3 ng/mL, p < 0.01).
LPS-stimulated production of 8-isoprostane, a biomarker of oxidative stress, was also markedly lower
in AAA compared to control participants. These findings are consistent with developed tolerance
in human AAA macrophages. As Toll-like receptor 4 (TLR4) has been implicated in tolerance,
macrophages were examined for changes in TLR4 expression and distribution. Although TLR4
mRNA and protein expression were unaltered in AAA, cytosolic internalization of receptors and lipid
rafts was found. These findings suggest the inflamed, pro-oxidant AAA microenvironment favors
macrophages with an endotoxin-tolerant-like phenotype characterized by a diminished capacity to
produce pro-inflammatory mediators that enhance the immune response.
Keywords: abdominal aortic aneurysm; endotoxin tolerance; lipid rafts; macrophages; toll-like
receptor 4 (TLR4)
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1. Introduction
Abdominal aortic aneurysm (AAA), characterized by a complex, multifactorial pathogenesis, is a
clinically silent vascular disease typically localized to the terminal aortic segment [1]. Degenerative by
nature, the condition is associated with chronic inflammatory cell infiltration and destructive remodeling
of aortic connective tissue that culminates in a focal loss of vessel wall integrity and full thickness
dilation of the abdominal aorta [2,3]. AAA initiation and progression is strongly associated with
aortic macrophage accumulation [4]. Macrophages, derived from circulating monocytes or monocyte
reservoirs in the spleen, are phagocytic immune cells with an ability to assume distinct polarization
states in response to environmental stimuli [5]. Polarization of macrophages extends along a continuum
of diverse phenotypes with the extreme ends (classically activated pro-inflammatory M1 macrophages
and alternatively activated anti-inflammatory M2 macrophages) most commonly recognized [6].
An examination of macrophage cell surface markers in human aneurysmal infrarenal aortic
wall sections demonstrated that M1 macrophages are predominant in the aortic adventitia while
CD206+ (M2) macrophages are localized to the intraluminal thrombus [7]. Studies examining M1/M2
markers in human AAA indicate M1-produced inflammation amplifying cytokines predominate in
abdominal aortic aneurysmal disease and suggest a major role for the M1 macrophage phenotype [8].
Macrophages, however, display functional plasticity and possess a remarkable ability to modulate their
phenotypic and functional properties in response to tissue-derived cues and signals arising from the local
environment [9]. For example, in atherosclerotic disease, the oxidized phospholipid-rich environment
directs a macrophage phenotype that is characterized by abundant over-expression of nuclear factor
erythroid 2-related factor 2 (Nrf2)-mediated redox-regulatory genes and low phagocytotic capacity [10].
Similarly, in cancer, tumor-associated macrophages are reported to adopt unique phenotypes that
facilitate the growth of tumors and aid their subsequent survival [11]. It is thus conceivable that,
in AAA, exposure of macrophages to an inflamed, oxidized microenvironment favors the generation
of cells with dramatically altered physiology and behavior. While the phenotypes of macrophages in
AAA are well documented, the environmentally conditioned responses of these cells to inflammatory
stimuli remain to be established. Using a series of case–control experiments, we explored the possibility
that the unique AAA microenvironment shapes or directs the responses of differentiated macrophages
to persistent inflammatory insults.
2. Materials and Methods
All data and materials have been made available at Figshare Knowledge at Figshare.com and
can be accessed at: 10.6084/m9.figshare.6291785. The manuscript complies with the Strengthening the
Reporting of Observational studies in Epidemiology (STROBE) and Meta-analysis of Observational
Studies in Epidemiology (MOOSE) reporting guidelines for observational studies.
2.1. Participants and Eligibility Criteria
A case-control study design was used to compare patients with AAA and healthy control
participants (Table 1) who were recruited from the Sunshine Coast community between June 2016
and May 2017. Participants included members of the University of the Third Age (U3A) and patients
of a Sunshine Coast vascular clinic. Male participants only were recruited to this study as AAA is
more prevalent in men than in women and sex differences exist with respect to AAA morphology and
hemodynamics. The study was approved by the University of the Sunshine Coast (A/15/705) and the
Prince Charles Hospital Human Research Ethics Committees (HREC/16/QPCH/114). All experiments
were performed in accordance with relevant guidelines and regulations. Written informed consent was
obtained for each participant and all consented participants completed the study. The patient group
for biomarker experiments included 19 men with AAA (30–45 mm diameter) and the control group
included 36 men without a documented AAA. The patient group for lipid raft and Toll-like receptor
4 (TLR4) imaging experiments included 14 men with AAA (30–45 mm diameter) and the control
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group included 8 men without a documented AAA. AAA patient aneurysm size was confirmed with
ultrasound at study entry. Exclusion criteria for the biomarker experiments were: age < 60 or > 86 years,
body mass index (BMI) above 39 kg m−2, uncontrolled hypertension (systolic blood pressure (SBP)
≥ 140 mm Hg and diastolic blood pressure (DBP) ≥ 90 mm Hg), cardiac arrhythmia, heart failure,
symptomatic aortic stenosis, chronic obstructive pulmonary disease, chronic inflammatory disease
and regular use of prescription anti-inflammatory medication. A family history of AAA or known
aneurysmal disease served as additional exclusion criteria for control participants. All participants
refrained from non-prescribed anti-inflammatory medications 72 h prior to blood collection and
abstained from alcohol and caffeine for the 12 h leading up to their visit.
Table 1. Demographic, biometric and medical characteristics of abdominal aortic aneurysm (AAA)
patients and control participants. Continuous demographic data are presented as mean± SD, categorical
demographic data are presented as number (percentage).
Biomarker Experiments Confocal Experiments
Variable
AAA
Patients
(n = 19)
Control
Participants
(n = 36)
AAA
Patients
(n = 14)
Control
Participants
(n = 8)
Gender (Male/Female) 19/0 36/0 14/0 8/0
Age (years) 74.6 ± 5.8 71.7 ± 5.2 73.0 ± 4.92 69.7 ± 5.15
AAA size (mm) 37.8 ± 5.3 37.0 ± 5.5
Smoking: Never 7 16 3 3
Past 10 20 9 4
Current 2 0 2 1
BMI (kg/m2) 26.9 ± 2.9 25.8 ± 3.4 27.5 ± 3.6 24.9 ± 4.0
Systolic blood pressure (mmHg) 136.5 ± 13.6 135.9 ± 11.3 142.1 ± 14.7 131.3 ± 14.4
Diastolic blood pressure (mmHg) 78.6 ± 6.1 79.6 ± 8.3 81.0 ± 7.6 84.0 ± 4.2
Coronary heart disease 12 (63%) † 3 (8%) 5 (35%) 0 (0%)
Diabetes 2 (11%) 0 (0%) 0 (0%) 0 (0%)
Dyslipidemia 15(79%) † 9 (25%) 9 (64%) 2 (25%)
Hypertension 12 (63%) 13 (36%) 9 (64%) 3 (38%)
NSAIDs 5 (26%) 3 (8%) 2 (14%) 0 (0%)
Ace inhibitors 2 (11%) 2 (6%) 2 (14%) 1 (13%)
Alpha-1 blockers 0 (0%) 2 (6%) 0 (0%) 0 (0%)
AT receptor antagonists 6 (32%) 6 (17%) 3 (21%) 2 (25%)
Beta blockers 8 (42%) † 4 (11%) 2 (14%) 2 (25%)
Calcium channel blockers 2 (11%) 3 (8%) 3 (21%) 2 (25%)
Diuretics 2 (11%) 1 (3%) 0 (0%) 0 (0%)
Anti-platelet drugs 10 (53%) † 2 (6%) 7 (50%) 1 (13%)
Statins 14 (74%) † 10 (28%) 9 (64%) 2 (25%)
† AAA significantly different to control (Fisher’s exact test, p < 0.05). Prostaglandin PGE2 data were measured using
plasma from both AAA cohorts.
2.2. Monocyte Isolation Protocol
Monocytes were isolated as previously described, using Ficoll-Paque Premium 1.073 (GE
Healthcare, Uppsala, Sweden) [12] and hyperosmotic Percoll Plus (Sigma-Aldrich, St. Louis, MO,
USA; prepared as described by Repnick et al. [13]) or by discontinuous density centrifugation using
isotonic Percoll Plus (Sigma-Aldrich, St. Louis, MO, USA) at densities 1.070 g mL−1, 1.062 g mL−1,
1.060 g mL−1 and 1.058 g mL−1. Monocytes within a band located at the interface of the Percoll solution
and DPBS/media were collected and diluted with 4 mL of Ca2+/Mg2+ free DPBS containing 1 mmol L−1
EDTA. An aliquot of the cells was stained with May-Grunwald stain (Merck Millipore, Burlington,
MA, USA) to confirm the presence of monocytes [14].
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2.3. Macrophage Maturation and Activation
Monocytes matured into a morphologically heterogeneous macrophage population over 7 days.
Macrophages were characterized by excellent purity (98.6 ± 0.6%) and intact activation and phagocytic
activities [12]. On day 7, Iscove’s Modified Dulbecco’s Medium (IMDM) and all additives except
Macrophage Colony Stimulating Factor (M-CSF)) was replaced for a final time and the adherent
macrophages were exposed to 20 ng mL−1 interferon gamma (IFN-γ, Sigma-Aldrich, St. Louis, MO, USA)
and 0.1 µg mL−1 Escherichia coli-derived lipopolysaccharide (LPS) (Serotype 0111:B4; Sigma-Aldrich,
St. Louis, MO, USA) for 24 h. All supernatants were collected, centrifuged (10,000× g, 5 min, 4 ◦C) and
aliquoted with and without butylhydroxytoluene (BHT; 2.5 mg mL−1, Sigma-Aldrich, St. Louis, MO,
USA). For Western blot analysis, cells were collected in a 300 µL aliquot of radioimmunoprecipitation
assay (RIPA) buffer (150 mmol L−1 NaCl (BioLab, Clayton, Victoria, Australia), 20 mmol L−1 Tris-HCl
(Sigma-Aldrich, St. Louis, MO, USA), 1% Igepal CA-630 (Sigma-Aldrich, St. Louis, MO, USA),
0.1% sodium dodecyl sulphate (Sigma-Aldrich, St. Louis, MO, USA), 1% sodium deoxycholate
(Sigma-Aldrich, St. Louis, MO, USA), 1 complete protease inhibitor tablet per 7 mL (Roche Diagnostics
GmbH, Mannheim, Germany), pH 7.4) and stored at −80 ◦C until analysis. For glutathione peroxidase
(GPx) activity assays, a 300 µL aliquot of GPx collection buffer (50 mmol L−1 Tris-HCl, pH 7.5,
5 mmol L−1 EDTA (BioLab, Clayton, Victoria, Australia), 1 mmol L−1 DTT (Sigma-Aldrich, St. Louis,
MO, USA)) was added to each well and adherent cells were harvested and stored as before. For
catalase activity assays, a 300 µL aliquot of catalase collection buffer (50 mmol L−1 potassium phosphate
(BioLab, Clayton, Victoria, Australia), pH 7.0, containing 1 mmol L−1 EDTA) was added to each well
and adherent cells were harvested and stored as before.
2.4. Measurement of Free 8-Isoprostane and a Prostaglandin E2 Metabolite
To establish oxidative stress status, free 8-isoprostane levels were measured in BHT-preserved
plasma samples and monocyte-derived macrophage supernatants, as described previously [14].
2.5. Cytokine and MMP-9 Assays
Cytokines (interleukin-6 (IL-6), transforming growth factor-β (TGF-β), tumor necrosis factor alpha
(TNF-α), IL-1β and IL-10) were measured in plasma and monocyte-derived macrophage supernatants
and matrix metalloproteinase-9 (MMP-9) levels were measured in plasma using commercially
available enzyme immunoassay kits (Affymetrix eBioscience, San Diego, CA, USA) in accordance with
manufacturer’s instructions.
2.6. Antioxidant Assays
Catalase and GPx enzymatic activities were measured in plasma and monocyte-derived
macrophage lysates using commercially available kits (Cayman Chemical Company, Ann Arbor,
MI, USA) in accordance with manufacturer’s instructions. Enzyme activities were expressed per
µg protein.
2.7. Western Blot Analysis
Western blot analysis of monocyte-derived macrophage lysates was carried out to determine
expression levels of antioxidant enzymes, MMP-9, TLR4, interleukin-1 receptor-associated kinase 1
(IRAK1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Cell lysates were
mechanically homogenized for 2 s at maximum speed (TissueRuptor, QIAGEN PTY LTD Australia,
Chadstone, Victoria, Australia) and centrifuged (10,000× g, 10 min, 4 ◦C). The supernatants were
collected and balanced for protein concentration. Samples were heated in 2× loading buffer (95 ◦C;
5 min) and transferred to 7.5% or 12% precast polyacrylamide gels (Bio-Rad Laboratories, Gladesville,
NSW, Australia). Proteins were separated by electrophoresis (150 V, 48–70 min, 22 ◦C) in running buffer
(25 mmol L−1 Tris base (Sigma-Aldrich, St. Louis, MO, USA), 192 mmol L−1 glycine (Sigma-Aldrich,
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St. Louis, MO, USA), 0.1% SDS (Sigma-Aldrich, St. Louis, MO, USA), pH ~8.3 without adjustment) and
transferred to Immobilon-P polyvinylidene difluoride (PVDF) membranes using a semi-dry transfer
cell (Bio-Rad Laboratories, Gladesville, NSW, Australia) at 15 V for 15 min. The membranes were
blocked with 3% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA) or 5% non-fat milk
in Tris-buffered saline (pH 7.6) with 0.1% Tween-20 for 60 min followed by overnight incubation with
antibodies to catalase (Abcam, Cambridge, UK, rabbit polyclonal, IgG, titer 2 µg mL−1, catalog number
ab16731), GPx (Cell Signaling Technology, Danvers, MA, USA, rabbit polyclonal, titer 1:50 dilution of
stock, catalog number 3206), MMP-9 (Cell Signaling Technology, Danvers, MA, USA, rabbit polyclonal,
titer 8.1 µg mL−1, catalog number 3852), TLR4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA,
mouse monoclonal, IgG1 (kappa light chain), titer 0.5 µg mL−1, catalog number SC-293072), NF-κB
(Cell Signaling Technology, rabbit IgG, titer 1:400 dilution of stock, catalog number 3033), IRAK1 (Cell
Signaling Technology, rabbit IgG, titer 1:400 dilution of stock, catalog number 4504) or glyceraldehyde
3-phosphate dehydrogenase (GAPDH; loading control; Abcam, mouse monoclonal [6C5], IgG1, titer
2.5 µg mL−1, catalog number ab8245). Bands were visualized using an IgG Vectastain kit (Vector
Laboratories Inc., Burlingame, CA, USA) and 3,3′-diaminobenzidine tetrahydrochloride (DAB) with
metal enhancer (Sigma-Aldrich, St. Louis, MO, USA). Image J software (NIH, Bethesda, MD, USA) was
used to quantify band intensity, with subtraction of background intensity from an adjacent region of
the membrane.
2.8. Confocal Microscopy
Human monocytes (1.3 × 105 cells per well) were seeded onto 8-well chamber slides (Sarstedt
Australia, Mawson Lakes, SA, Australia) and maintained in culture as described above. On day 7,
adherent macrophages were primed with 0.1 µg mL−1 LPS and 20 ng mL−1 IFN-γ for 24 h. At the end
of the priming period, culture supernatants were removed, and the cells were exposed to LPS and
IFN-γ for a second time (4 h). Cells were washed once with serum-free medium and labelled with
cholera toxin subunit B conjugated to Alexa Fluor 488 (Thermo Fisher Scientific, Seventeen Mile Rocks,
Queensland, Australia, catalog number C34775; 4 µg mL−1) for 20 min at 4 ◦C. Following three rinses
with serum-free medium, the cholera toxin subunit B was cross-linked with cholera toxin B-subunit
antibody (1:200 dilution, Millipore, goat polyclonal, IgG, Catalog number 227040; 15 min, 4 ◦C).
Cells were rinsed, fixed using formalin (3.7%, 5 min, 4 ◦C) and methanol (100%, 5 min, −20 ◦C), washed
with PBS (3× 5 min, 4 ◦C) and incubated with Image iT Fx signal enhancer (Life Technologies, Mulgrave,
Victoria, Australia; 30 min, room temperature). Cells were rinsed three times with PBS and incubated
overnight (4 ◦C) with anti-TLR4 mAb (Santa Cruz Biotechnology, mouse monoclonal, IgG1 (kappa
light chain), titer 0.2 µg mL−1, catalog number SC-293072; 0.2 µg mL−1) and DAPI (Sigma-Aldrich,
St. Louis, MO, USA, catalog number D9542-IMG; 2 µg mL−1). On the following day, cells were
washed with PBS (3 × 5 min, 4 ◦C) and incubated with goat anti-mouse IgG secondary antibody,
Alexa Fluor 568 (Thermo Fisher Scientific, F(ab′) 2-Goat anti-mouse IgG (H + L) cross-adsorbed
secondary antibody, titer 10 µg mL−1, catalog number A11019; 1 h, 4 ◦C). Cells were mounted with
glycerol and immobilized beneath glass coverslips. Confocal images were acquired using a Nikon
digital sight DS-QilMc monochrome camera (square pixel CCD, 1.5 megapixels; Nikon Corporation,
Tokyo, Japan) attached to a Nikon Eclipse Ti microscope. Redistribution of the pro-inflammatory LPS
receptor, TLR4, was investigated and cells used in these analyses were selected based on DAPI staining
without reference to TLR4 immunofluorescence to avoid bias. TLR4 antibody was validated using
Western blot analysis. Only a single band was detected at the appropriate molecular weight (95 kDa).
No fluorescence was detected by confocal microscopy when the primary antibody was omitted.
2.9. RNA Isolation and Real-Time Quantitative PCR
RNA isolation and real-time quantitative PCR was carried out as described by Meital et al. [12].
Primers for TLR4, Nrf2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were as described
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by Song et al. [15], Saw et al. [16], and Long et al. [17] respectively. All samples were analyzed in
duplicate and standards were analyzed in triplicate (technical replicate).
2.10. Data Analysis
Group size estimates of 6 (8-isoprostane) and 31 (PGE2) were calculated with 80% power (alpha
level of 0.05) using power/sample size (Univ. British Columbia, Vancouver, BC, Canada) and pooled
variance (Solvers statistics) calculators. Values were based on previously reported levels in healthy
controls (8-isoprostane, 32 ± 15.0 pg mL−1; PGE2, 19.9 ± 14.5 pg mL−1) and patients with AAA
(8-isoprostane, 56.0 ± 8.9 pg mL−1; PGE2, 38.8 ± 34.35 pg mL−1) [18,19]. Continuous demographic
data for AAA patients and control participants were compared using a Student’s t-test and are
presented as mean ± SD. Categorical demographic variables were compared using a Fisher’s exact
test. Data were assessed to determine normality (Shapiro–Wilk test) and homogeneity of variance
(Levene statistic). Experimental data are presented as median and between group differences
were examined by Mann-Whitney U analysis. Outliers in plasma cytokine data (TNF-α n = 2,
IL-6 n = 1 and TGF-β n = 1) were identified using the extreme Studentized deviate many-outlier
procedure [20] and were excluded from analysis. Mantel-Haenszel analysis revealed no confounding
influence of comorbidities (hypertension, hyperlipidemia and coronary heart disease) or drug therapies
(β-adrenoceptor antagonists, statins and low dose aspirin) for macrophage supernatant TNF-α and
IL-6 data (Table 2). Data were analyzed with Prism (GraphPad Software, La Jolla, CA, USA) and
statistical significance was set at p < 0.05.
Table 2. Mantel-Haenszel analysis of potential confounding variables.
Endpoint Variable Chi Square d.f. p Confounder
TNF-α Beta blockers 0.19 1 0.66 No
TNF-α Statins 1.18 1 0.28 No
TNF-α Low dose Aspirin 0.10 1 0.75 No
TNF-α Hyperlipidemia 0.56 1 0.46 No
TNF-α Hypertension 0.01 1 0.91 No
IL-6 Beta blockers 0.23 1 0.63 No
IL-6 Statins 0.00 1 0.96 No
IL-6 Hyperlipidemia 0.12 1 0.73 No
IL-6 Hypertension 0.17 1 0.68 No
IL-6 Coronary heart disease 0.66 1 0.42 No
d.f. Degrees of freedom.
3. Results
3.1. AAA Was Associated with Systemic Inflammation
Plasma concentrations of 8-isoprostane (Figure 1a) and TNF-α (Figure 1b) were markedly elevated
in AAA patients compared to control participants (p = 0.0018 and 0.0170). In contrast, concentrations
of IL-6 (Figure 1c), TGF-β (Figure 1d) and MMP-9 (Figure 1e) in AAA plasma were comparable to the
control cohort. The plasma concentration of a PGE2 metabolite was markedly lower in patients with
AAA compared to control participants (Figure 1f; p = 0.014), as was activity of the antioxidant enzyme
catalase (Figure 1g; p = 0.0096). GPx activity (Figure 1h) was similar across groups.
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Figure 1. Plasma 8-isoprostane and cytokine concentratio s an anti i t e e ctivity in patients
with small AAA and healthy control participants. Plasma 8-Isoprostane (a); AAA n = 10, control
n = 17) and tumor necrosis factor alpha (TNF-α; (b); AAA n = 19, control n = 34) concentrations were
markedly elevated and catalase activity (g); AAA n = 9, control n = 16) and PGE2 metabolite levels (f);
AAA n = 30, control n = 34) significantly reduced in AAA patients compared to control participants.
Interleukin-6 (IL-6; (c), transforming growth factor-β (TGF-β; (d), matrix metalloproteinase-9 (MMP-9;
(e) concentrations and glutathione peroxidase activity (GPx; (h) were similar across groups. Box plots
show 25th, 50th (median) and 75th percentiles ( orizont lines), mean (+) and minimum and maximum
values (whiskers). * p < 0.05 (Mann-Whitney analysis).
3.2. Macrophage Responses to LPS Stimulation Were Suppressed in AAA
LPS-stimulated 8-isoprostane production, expressed as a function of total number of circulating
monocytes present in whole blood, was markedly suppressed in AAA macrophage supernatants
(Figure 2b) compared to control participants (Figure 2a) with the slope of the control data (R2 = 0.93)
9.1-fold greater than that of the AAA data (R2 = 0.13, p = 0.0063). In addition, AAA macrophages
produced lower levels of TNF-α (Figure 2c) and IL-6 (Figure 2d) in response to LPS stimulation
compared to control participants (p = 0.0214 and 0.0045, respectively). Protein levels of both proMMP-9
(Figure 2f) and mature MMP-9 (Figure 2g) were markedly reduced in macrophage lysates from AAA
patients (35% and 40% of control band intensity, respectively; p = 0.0095 and 0.0381). A non-significant
trend for higher levels of TGF-β was observed in supernatants of macrophages from AAA patients
(Figure 2e) compared to control participants. Concentrations of IL-10 and IL-1β in AAA macrophage
supernatants were not different to control (IL-10, 0.22 ± 0.09 vs. 0.26 ± 0.05 ng mL−1; IL−1β, 3.3 ± 1.14
vs. 2.0 ± 0.46 pg mL−1). Catalase (Figure 2h) and GPx activity (Figure 2j) in LPS-stimulated AAA
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macrophage lysates was similar to control participants and no difference in the protein expression of
either enzyme (Figure 2i,k) was observed for the two cohorts.
Figure 2. Cytokine, 8-isoprostane and antioxidant enzyme activity levels in supernatants and lysates
obtained from AAA patient and control subject monocyte-derived macrophages. LPS-stimulated
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8-isoprostane production, expressed as a function of total number of circulating monocytes present
in whole blood samples, was markedly suppressed in AAA macrophage supernatants (b); n = 4)
compared to control participants (a); n = 5). AAA macrophages also produced lower concentrations of
tumor necrosis factor alpha (TNF-α; (c); n = 9) and interleukin-6 (IL-6; (d); n = 12) compared to control
macrophages (n = 17 and n = 14) and both pro-matrix metalloproteinase-9 (ProMMP-9; 92 kDa, (f))
and mature MMP-9 (84 kDa, (g)) protein levels were significantly reduced (both n = 6). Transforming
growth factor-β (TGF-β; (e)) concentrations tended to be higher in AAA macrophage supernatants
(AAA, n = 10; control, n = 14), although this did not achieve significance. Catalase activity ((h); AAA,
n = 7; control, n = 7) and expression ((i); AAA, n = 6; control, n = 4) and glutathione peroxidase (GPx)
activity ((j); AAA, n = 8; control, n = 8) and expression ((k); AAA, n = 6; control, n = 4) were similar to
the control cohort. Box plots show 25th, 50th (median) and 75th percentiles (horizontal lines), mean (+)
and minimum and maximum values (whiskers). * p < 0.05 (Mann–Whitney analysis).
3.3. Nrf2 mRNA Transcripts Were Increased in AAA Macrophages
Nuclear factor erythroid 2-related factor 2 mRNA levels were significantly higher in both
non-stimulated (p = 0.027) and 24 h LPS-stimulated macrophages (p = 0.003) from patients with AAA
compared to control (Figure 3).
Figure 3. Comparison of relative levels of Nrf2 transcripts in macrophages from control participants
and patients with AAA. Nrf2 mRNA levels, measured by real time qPCR, were normalized to GAPDH.
Nrf2 mRNA was significantly increased in both non-stimulated and 24 h LPS-stimulated (n = 8) AAA
macrophages compared to control (n = 9). * p < 0.05.
3.4. Lipid Raft and TLR4 Internalization Was Observed in AAA Macrophages
In control participants, in the absence of LPS stimulation (Figure 4a,b) and following 40 min LPS
stimulation (Figure 4e,g), lipid rafts were localized to the plasma membrane of macrophages with
no evidence of lipid raft internalization. Following a 28 h exposure to LPS (Figure 4i,j), lipid raft
internalization was observed in all cells. In AAA macrophages, lipid raft internalization was observed in
both the non-stimulated (Figure 4m,n) and LPS-stimulated (Figure 4q,r) conditions. TLR4 was localized
to the plasma membrane of non-stimulated (Figure 4a,c) and 40 min LPS-stimulated (Figure 4e,g) control
macrophages but not AAA macrophages in either the non-stimulated (Figure 4m,o) or LPS-stimulated
(Figure 4q,s) conditions. TLR4 was diffusely localized within the cytosol in 28 h LPS-stimulated
macrophages from control (Figure 4i,k) and AAA (Figure 4q,s) participants. AAA macrophage lysate
TLR4 mRNA (Figure 4u) and protein concentration (Figure 4v) were similar to the control.
Antioxidants 2020, 9, 896 10 of 17Antioxidants 2020, 9, x FOR PEER REVIEW 8 of 19 
 8
 
  
Control 
AAA 
Composite      Lipid rafts         TLR4           DAPI   
Media 
40 min 
LPS 
28 h 
LPS 
Media 
28 h 
LPS 
(a) (b) (c) (d) 
(f) (g) (h) 
(i) (j) (k) (l) 
(m) (n) (o) (p) 
(q) (r) (s) (t) 
(e) 
(u) (v) 
95 kDa 
36 kDa 
TLR4 
GAPDH 
Co
nt
ro
l N
on
AA
A N
on
0
2
4
6
M
ac
ro
ph
ag
e 
Ly
sa
te
 
TL
R4
 m
RN
A
Figure 4. Representative images showing differential distribution of lipid rafts and TLR4 in human
monocyte-derived macrophages before (control, a–d; AAA, m–p) and after 40 min LPS stimulation
(control, e–h) or 28 h LPS stimulation (control, i–l; AAA, q–t). Lipid rafts were localized to the
membrane of non-stimulated (a,b) and 40 min LPS-stimulated macrophages from n = 8/8 control
participants (e,f) and lipid raft internalization was observed in n = 8/8 control participant macrophages
following 28 h LPS stimulation (i,j). Lipid rafts were internalized in macrophages from n = 7/10 AAA
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participants in the non-stimulated condition (m,n) and in n = 10/10 AAA participant macrophages
following exposure to 28 h LPS (q,r). TLR4 was localized to the membrane of non-stimulated (a,c)
and 40 min LPS-stimulated control macrophages (e,g). TLR4 was associated with the cytosol and
membrane of control macrophages exposed to LPS for 28 h (i,k). TLR4 was primarily internalized in
non-stimulated (m,o) and 28 h LPS-stimulated macrophages from the AAA participants (q,s). AAA
macrophage lysate TLR4 mRNA (u; AAA, n = 9; control, n = 8) and protein levels (v; AAA, n = 7;
control, n = 5) were similar to the control. TLR4 mRNA and protein levels were normalized to GAPDH.
No fluorescence was detected by confocal microscopy when the primary antibody was omitted (data
not shown). Red—Alexa Fluor 568-labelled TLR4; blue—DAPI; green—fluorescein isothiocyanate
(FITC)-labelled cholera toxin subunit B (detects GM1 ganglioside lipid raft marker). Scale bar = 20 µm.
3.5. Levels of IRAK1 and Phosphorylated NF-κB Were Significantly Decreased in AAA
Protein levels of interleukin-1 receptor-associated kinase 1 (IRAK1) were lower in non-stimulated
macrophages from patients with AAA (n = 9) compared to control (n = 6; p = 0.02) (Figure 5a).
IRAK1 mRNA transcript levels were not different between the groups (Figure 5b). Levels of
phosphorylated NF-κB p65 protein subunit were significantly lower in non-stimulated macrophages
from patients with AAA (n = 11) compared to control (n = 7; p = 0.04) (Figure 5c).
Figure 5. Protein (a) and mRNA transcript levels of interleukin-1 receptor-associated kinase 1
(IRAK1) (b) and phosphorylation levels of the p65 protein subunit of NF-κB (c) in control and AAA
monocyte-derived macrophages. Values are mean ± SEM. * p < 0.05.
4. Discussion
Systemic inflammation and oxidative stress are hallmark features of AAA and are well-documented
to underlie the various pathological processes contributing to the progression of this disease [21].
In support of this, our data showed increased circulating levels of TNF-α and the oxidative stress
biomarker 8-isoprostane and reduced activity of the antioxidant enzyme catalase in plasma samples
from patients with AAA. Elevated levels of TNF-α have consistently been identified in AAA tissue [22],
plasma [23] and serum [24] and there is evidence that the concentration of this cytokine is higher in
patients with small compared to large AAA [25]. In contrast, the association between 8-isoprostane
levels and AAA or catalase activity and AAA has been examined in few studies involving human
participants despite compelling evidence linking impaired systemic redox status to multiple AAA
mechanical and molecular events [26,27]. A study by Pincemail et al. [28] identified an 18% increase in
urinary levels of 8-isoprostane in patients with small AAA and a 66% increase in patients with large
AAA (>50 mm) compared to an age-matched non-AAA control group. Similarly, Ramos-Mozo and
colleagues [29] reported markedly decreased catalase activity levels in plasma samples obtained from
103 asymptomatic patients with small (n = 56) and large (n = 47) AAA compared to a non-AAA control
cohort (n = 34). Taken together, the results obtained add to accruing evidence that AAA is a chronic
vascular disease underpinned by systemic inflammation and a pathological state of oxidative stress.
Environmental cues shape adaptive macrophage responses that either induce resolution and repair
mechanisms or allow progression toward a protracted disease state. Endotoxin tolerance, which is
a prime example of such shaping, mitigates against tissue damage caused by excessive activation
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of macrophages in an acute setting [30]. In AAA, it is conceivable that exposure to LPS-secreting
Gram negative bacteria [31], cleaved extracellular matrix components [32] or an increased circulating
concentration of fibrinogen [33], provide a level of endogenous danger signaling sufficient to prime
macrophage TLR4 towards an endotoxin tolerant state. In line with this hypothesis, our study
provides the first evidence that AAA macrophages exhibit a refractory phenotype characterized by
suppressed production of inflammatory cytokines, oxidative stress biomarkers and elastolytic enzymes
following LPS challenge. The abrogated TNF-α and IL-6 response and downregulation of MMP-9
identified in AAA macrophages is characteristic of endotoxin tolerance as described by evidence from
human studies [34,35]. Data arising from microarray studies [36,37] indicate that a subset of LPS
response genes, termed non-tolerizeable genes (e.g., IL-1β), show equivalent or upregulated expression
levels following re-exposure to inflammatory stimuli. Consistent with this, AAA monocyte-derived
macrophages produced similar levels of IL-10 and IL-1β compared to a control cohort and showed
a trend toward increased production of TGF-β. The combined evidence suggests that the inflamed,
oxidized AAA microenvironment skews macrophages toward an immunosuppressed endotoxin
tolerant-like phenotype that is less equipped to stimulate resolution-directed innate immune responses.
While endotoxin tolerance has been reported to protect against uncontrolled systemic inflammation,
tissue damage and septic shock lethality in animal models of disease [38,39], there is evidence
that macrophage tolerization may be deleterious in the context of human disease. For example,
chronic suppression of the immune response in pathologies such as sepsis can lead to long-lasting
inflammation, opportunistic infection and, in some instances, death [40,41]. In sepsis patients in
particular, decreased monocyte human leukocyte antigen-DR (HLA-DR) expression, an established
surrogate marker of immunosuppression, has consistently been shown to independently predict the
occurrence of nosocomial infection and mortality [42,43]. While the impact of endotoxin tolerant-like
immunosuppression on AAA disease progression has yet to be determined, a growing number of
reports have linked diminished immune capacity in AAA with adverse clinical disease outcomes.
For example, preventive IL-6 neutralization in an animal model of AAA increased 7-day mortality by
>40% [44] and studies examining the disease course of AAA in organ transplant patients have reported
aggressive expansion and accelerated rupture rates following commencement of immunosuppressive
treatment regimen [45,46].
This study examined tolerizing mechanisms in monocyte-derived macrophages at the mRNA,
receptor and lipid raft level. We measured Nrf2 mRNA levels in macrophages from AAA patients
and control participants in light of recent evidence suggesting this transcription factor negatively
regulates macrophage responses to LPS [47]. We found significantly upregulated Nrf2 mRNA levels
in both non-stimulated and LPS-stimulated macrophages from patients with AAA compared to the
control. As Nrf2 is reported to inhibit pro-inflammatory cytokine gene expression in M1 macrophages
through direct binding to DNA, it is possible that this transcription factor represents a tolerizing
mechanism in AAA. We next investigated the distribution of TLR4 and lipid rafts in macrophages
isolated from patients with AAA using confocal microscopy. We found that TLR4 and lipid raft
localization was diffusely cytosolic in AAA macrophages in both the non-stimulated and LPS-stimulated
conditions whereas in control participant macrophages, these were mainly localized to the plasma
membrane. It is well established that ligand-induced activation of TLR4 occurs within cholesterol-
and sphingolipid-enriched membrane rafts in concert with the co-receptor, cluster of differentiation 14
(CD14), at the plasma membrane [48]. This makes it likely that the low association of TLR4 and lipid
rafts with the plasma membrane in AAA macrophages contributes to the suppressed response of these
innate immune cells to stimulation by LPS. The abrogated TLR4 signaling that accompanies tolerance
in cells of human origin has previously been shown to occur in the absence of downregulation of
the receptor [49]. In line with this, our study found similar TLR4 mRNA and protein levels in AAA
macrophages compared to the control.
To further explore the phenomenon of attenuated signaling within this pro-inflammatory
pathway, mRNA and protein levels of the kinase IRAK1 and protein levels of NF-κB, a transcription
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factor downstream of TLR4 were examined. IRAK1 is activated by the TLR4 adaptor MyD88
and diminished levels of this protein have a crucial role in endotoxin tolerance [50]. In addition,
decreased phosphorylation of NF-κB p65 subunit is strongly associated with endotoxin tolerance [51,52].
Lower IRAK1 protein levels and reduced NF-κB phosphorylation observed in this study concur with
the observed abrogated TLR4 signaling in AAA and highlight these as potential mechanisms involved
in tolerance induction.
The lower levels of PGE2 in AAA patient plasma are of interest. PGE2 mediates initiation
of inflammatory responses, moderation of inflammatory response magnitude and duration and,
in later stages, activation of eicosanoid switching toward pathways of resolution and healing [53].
Decreased PGE2 production in AAA raises the possibility that impaired eicosanoid switching may be a
contributory factor in the non-resolving inflammation that is a hallmark feature of AAA.
Limitations
A limitation of this study was the absence of ultrasound screening for AAA in control
participants. While an in vitro cell culture system is subject to inherent limitations, our use of native,
non-immortalized and non-transformed primary cells allowed a biologically relevant representation of
the unique, cell-specific responses of AAA macrophages to an LPS stimulus. In addition, the functional
changes/responses observed for monocyte-derived macrophages are likely to be indicative of
macrophages within the AAA aorta as aneurysmal macrophages derive primarily from a circulating
monocyte precursor. The evidence for endotoxin tolerance in patients with AAA was obtained by
examining blood-derived macrophages in a cell culture environment and, while phenotypic changes
are possible during cell culture, comparisons between patients with AAA and control subjects were
made using cells that were grown under identical conditions. In addition, a previous study examining
macrophage subtypes has reported that cells isolated by laser capture microdissection in AAA tissue
demonstrate similar gene expression profiles to those obtained in vitro [7], suggesting that cellular
changes occurring during or after cell harvest may be minor. While MMP-9 protein concentration and
Nrf2 mRNA expression was reported for macrophage lysates, further studies could correlate these
end-points with their activity. Further studies are also warranted to examine evidence of endotoxin
tolerance in human AAA macrophages in situ, and to investigate whether similar responses are
observed in macrophages obtained from female patients who have AAA.
5. Conclusions
Taken together, the results reported here indicate that, against a background of chronic systemic
inflammation and oxidative stress, AAA macrophages adopt an endotoxin tolerant-like phenotype that
is characterized by a diminished capacity to produce mediators that enhance the immune response.
Diminished immune capacity in AAA may exacerbate the persistent inflammation and consequent
failure of resolution that underlies this disease state. In this setting, strategies aimed at reversing
tolerance may provide some benefit. Tolerance thus represents an area of investigation with the
potential to yield biologically plausible therapeutic targets.
Author Contributions: Conceptualization, L.T.M., A.V.K., C.D.A. and F.D.R.; methodology, L.T.M., A.E.M., J.G.,
A.V.K., C.D.A. and F.D.R.; validation, L.T.M., A.E.M., A.V.K. and F.D.R.; formal analysis, L.T.M., A.V.K. and F.D.R.;
investigation, L.T.M., M.T.W., A.E.M., M.P., A.V.K. and F.D.R.; resources, M.T.W., K.S., R.M., J.O., P.J., C.Y.M., M.P.,
J.G. and T.G.B.; data curation, L.T.M., A.E.M., A.V.K. and F.D.R.; writing—Original draft preparation, L.T.M.,
C.Y.M., T.G.B., C.D.A. and F.D.R.; writing—Review and editing, L.T.M., M.T.W., A.E.M., K.S., R.M., J.O., P.J.,
C.Y.M., M.P., S.C., J.G., A.V.K., T.G.B., C.D.A. and F.D.R. supervision, J.O., S.C., A.V.K., C.D.A. and F.D.R.; project
administration, R.M., S.C. and F.D.R.; funding acquisition, J.G. and F.D.R. All authors have read and agreed to the
published version of the manuscript.
Funding: This study was supported by Wishlist—Sunshine Coast Health Foundation, and the School of Health
and Sport Science, University of the Sunshine Coast. JG holds a Practitioner Fellowship from the National
Health and Medical Research Council (1117061) and a Senior Clinical Research Fellowship from the Queensland
Government, Australia.
Antioxidants 2020, 9, 896 14 of 17
Acknowledgments: The authors thank Digby Krastins and Peter Young for their assistance with the blood
collection, and Lucia Pemble, Suzanne Ryan, Sandra Allen and Jill Webber for their assistance with AAA
patient recruitment.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
AAA Abdominal aortic aneurysm
BHT Butylhydroxytoluene
DPBS Dulbecco’s phosphate buffered solution
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-linked immunosorbent assay
GPx Glutathione peroxidase
IFN-γ Interferon gamma
IL-1β Interleukin-1 beta
IL-6 Interleukin-6
IMDM Iscove’s Modified Dulbecco’s Medium
IRAK1 Interleukin-1 receptor-associated kinase 1
LPS Lipopolysaccharide
M-CSF Macrophage colony-stimulating factor
MMP-9 Matrix metalloproteinase 9
mRNA Messenger RNA
NF-κB Nuclear factor kappa B
Nrf2 Nuclear factor E2-related factor 2
NSAID Non-steroidal anti-inflammatory drug
PGE2 Prostaglandin E2
qPCR Quantitative polymerase chain reaction
RIPA Radioimmunoprecipitation assay
TGF-β Transforming growth factor beta
TLR4 Toll-like receptor 4
TNF-α Tumor necrosis factor alpha
References
1. Nordon, I.M.; Hinchliffe, R.J.; Loftus, I.M.; Thompson, M.M. Pathophysiology and epidemiology of abdominal
aortic aneurysms. Nat. Rev. Cardiol. 2011, 8, 92–102. [CrossRef] [PubMed]
2. Michel, J.-B.; Martin-Ventura, J.-L.; Egido, J.; Sakalihasan, N.; Treska, V.; Lindholt, J.; Allaire, E.;
Thorsteinsdottir, U.; Cockerill, G.; Swedenborg, J. Novel aspects of the pathogenesis of aneurysms of
the abdominal aorta in humans. Cardiovasc. Res. 2011, 90, 18–27. [CrossRef] [PubMed]
3. Abdul-Hussien, H.; Hanemaaijer, R.; Kleemann, R.; Verhaaren, B.F.; van Bockel, J.H.; Lindeman, J.H.
The pathophysiology of abdominal aortic aneurysm growth: Corresponding and discordant inflammatory
and proteolytic processes in abdominal aortic and popliteal artery aneurysms. J. Vasc. Surg. 2010, 51,
1479–1487. [CrossRef] [PubMed]
4. Dale, M.A.; Ruhlman, M.K.; Baxter, B.T. Inflammatory cell phenotypes in AAAs: Their role and potential as
targets for therapy. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 1746–1755. [CrossRef]
5. Canton, J.; Khezri, R.; Glogauer, M.; Grinstein, S. Contrasting phagosome pH regulation and maturation in
human M1 and M2 macrophages. Mol. Biol. Cell 2014, 25, 3330–3341. [CrossRef]
6. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Invest. 2012, 122,
787–795. [CrossRef]
7. Boytard, L.; Spear, R.; Chinetti-Gbaguidi, G.; Acosta-Martin, A.E.; Vanhoutte, J.; Lamblin, N.; Staels, B.;
Amouyel, P.; Haulon, S.; Pinet, F. Role of proinflammatory CD68+ mannose receptor−macrophages in
peroxiredoxin-1 expression and in abdominal aortic aneurysms in humans. Arterioscler. Thromb. Vasc. Biol.
2013, 33, 431–438. [CrossRef]
8. Lindqvist, M.; Wallinder, J.; Henriksson, A.E. Soluble urokinase plasminogen activator receptor in patients
with abdominal aortic aneurysm. Thromb. Res. 2012, 130, 511–513. [CrossRef]
Antioxidants 2020, 9, 896 15 of 17
9. Biswas, S.K.; Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat. Immunol. 2010, 11, 889. [CrossRef]
10. Kadl, A.; Meher, A.K.; Sharma, P.R.; Lee, M.Y.; Doran, A.C.; Johnstone, S.R.; Elliott, M.R.; Gruber, F.;
Han, J.; Chen, W. Identification of a novel macrophage phenotype that develops in response to atherogenic
phospholipids via Nrf2. Circ. Res. 2010, 107, 737–746. [CrossRef]
11. Espey, M.G. Tumor macrophage redox and effector mechanisms associated with hypoxia. Free Radic. Biol. Med.
2006, 41, 1621–1628. [CrossRef] [PubMed]
12. Meital, L.T.; Coward, A.S.; Windsor, M.; Bailey, T.G.; Kuballa, A.; Russell, F.D. A simple and effective
method for the isolation and culture of human monocytes from small volumes of peripheral blood.
J. Immunol. Methods 2019, 472, 75–78. [CrossRef]
13. Repnik, U.; Knezevic, M.; Jeras, M. Simple and cost-effective isolation of monocytes from buffy coats.
J. Immunol. Methods 2003, 278, 283–292. [CrossRef]
14. Meital, L.T.; Windsor, M.T.; Perissiou, M.; Schulze, K.; Magee, R.; Kuballa, A.; Golledge, J.; Bailey, T.G.;
Askew, C.D.; Russell, F.D. Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages
from patients with small abdominal aortic aneurysm. Sci. Rep. 2019, 9, 12978. [CrossRef]
15. Song, Y.; Hou, M.; Li, Z.; Luo, C.; Ou, J.-S.; Yu, H.; Yan, J.; Lu, L. TLR4/NF-κB/Ceramide signaling contributes
to Ox-LDL-induced calcification of human vascular smooth muscle cells. Eur. J. Pharmacol. 2017, 794, 45–51.
[CrossRef] [PubMed]
16. Saw, C.L.L.; Cintron, M.; Wu, T.Y.; Guo, Y.; Huang, Y.; Jeong, W.S.; Kong, A.N.T. Pharmacodynamics of
dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and
antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos. 2011, 32, 289–300. [CrossRef]
[PubMed]
17. Long, J.; Zhao, J.; Yan, Z.; Liu, Z.; Wang, N. Antitumor effects of a novel sulfur-containing hydroxamate
histone deacetylase inhibitor H40. Int. J. Cancer 2009, 124, 1235–1244. [CrossRef]
18. Lee, E.E.; Eyler, L.T.; Wolkowitz, O.M.; Martin, A.S.; Reuter, C.; Kraemer, H.; Jeste, D.V. Elevated plasma
F2-isoprostane levels in schizophrenia. Schizophr. Res. 2016, 176, 320–326. [CrossRef]
19. Lindsay, T.F.; Luo, X.P.; Lehotay, D.C.; Rubin, B.B.; Anderson, M.; Walker, P.M.; Romaschin, A.D. Ruptured
abdominal aortic aneurysm, a “two-hit” ischemia/reperfusion injury: Evidence from an analysis of oxidative
products. J. Vasc. Surg. 1999, 30, 219–228. [CrossRef]
20. Rosner, B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983, 25, 165–172.
[CrossRef]
21. Guzik, B.; Sagan, A.; Ludew, D.; Mrowiecki, W.; Chwała, M.; Bujak-Gizycka, B.; Filip, G.; Grudzien, G.;
Kapelak, B.; Z˙mudka, K. Mechanisms of oxidative stress in human aortic aneurysms—association with
clinical risk factors for atherosclerosis and disease severity. Int. J. Cardiol. 2013, 168, 2389–2396. [CrossRef]
[PubMed]
22. Lindeman, J.H.; Abdul-Hussien, H.; Schaapherder, A.F.; Bockel, J.H.V.; Thüsen, J.H.V.D.; Roelen, D.L.;
Kleemann, R. Enhanced expression and activation of pro-inflammatory transcription factors distinguish
aneurysmal from atherosclerotic aorta: IL-6-and IL-8-dominated inflammatory responses prevail in the
human aneurysm. Clin. Sci. 2008, 114, 687–697. [CrossRef] [PubMed]
23. Ahnström, J.; Gottsäter, A.; Lindblad, B.; Dahlbäck, B. Plasma concentrations of apolipoproteins AI, B and M
in patients with abdominal aortic aneurysms. Clin. Biochem. 2010, 43, 407–410. [CrossRef] [PubMed]
24. Juvonen, J.; Surcel, H.-M.; Satta, J.; Teppo, A.-M.; Bloigu, A.; Syrjälä, H.; Airaksinen, J.; Leinonen, M.;
Saikku, P.; Juvonen, T. Elevated circulating levels of inflammatory cytokines in patients with abdominal
aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2843–2847. [CrossRef] [PubMed]
25. Hamano, K.; Li, T.-S.; Takahashi, M.; Kobayashi, T.; Shirasawa, B.; Ito, H.; Zempo, N. Enhanced tumor
necrosis factor-α expression in small sized abdominal aortic aneurysms. World J. Surg. 2003, 27, 476–480.
[CrossRef]
26. Morimoto, K.; Hasegawa, T.; Tanaka, A.; Wulan, B.; Yu, J.; Morimoto, N.; Okita, Y.; Okada, K. Free-radical
scavenger edaravone inhibits both formation and development of abdominal aortic aneurysm in rats.
J. Vasc. Surg. 2012, 55, 1749–1758. [CrossRef]
27. Yajima, N.; Masuda, M.; Miyazaki, M.; Nakajima, N.; Chien, S.; Shyy, J.Y. Oxidative stress is involved in
the development of experimental abdominal aortic aneurysm: A study of the transcription profile with
complementary DNA microarray. J. Vasc. Surg. 2002, 36, 379–385. [CrossRef]
Antioxidants 2020, 9, 896 16 of 17
28. Pincemail, J.; Defraigne, J.-O.; Cheramy–Bien, J.; Dardenne, N.; Donneau, A.-F.; Albert, A.; Labropoulos, N.;
Sakalihasan, N. On the potential increase of the oxidative stress status in patients with abdominal aortic
aneurysm. Redox Rep. 2012, 17, 139–144. [CrossRef]
29. Ramos-Mozo, P.; Madrigal-Matute, J.; Martinez-Pinna, R.; Blanco-Colio, L.M.; Lopez, J.A.; Camafeita, E.;
Meilhac, O.; Michel, J.-B.; Aparicio, C.; de Ceniga, M.V. Proteomic analysis of polymorphonuclear neutrophils
identifies catalase as a novel biomarker of abdominal aortic aneurysm: Potential implication of oxidative
stress in abdominal aortic aneurysm progression. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 3011–3019.
[CrossRef]
30. Seeley, J.J.; Ghosh, S. Molecular mechanisms of innate memory and tolerance to LPS. J. Leukoc. Biol. 2017,
101, 107–119. [CrossRef]
31. Vikatmaa, P.; Lajunen, T.; Ikonen, T.S.; Pussinen, P.J.; Lepäntalo, M.; Leinonen, M.; Saikku, P. Chlamydial
lipopolysaccharide (cLPS) is present in atherosclerotic and aneurysmal arterial wall—cLPS levels depend on
disease manifestation. Cardiovasc. Pathol. 2010, 19, 48–54. [CrossRef] [PubMed]
32. Fernandez-Moure, J.S.; Vykoukal, D.; Davies, M.G. Biology of aortic aneurysms and dissections.
Methodist Debakey Cardiovasc. J. 2011, 7, 2–7. [CrossRef] [PubMed]
33. Takagi, H.; Manabe, H.; Kawai, N.; Goto, S.; Umemoto, T. Plasma fibrinogen and D-dimer concentrations are
associated with the presence of abdominal aortic aneurysm: A systematic review and meta-analysis. Eur. J.
Vasc. Endovasc. Surg. 2009, 38, 273–277. [CrossRef]
34. del Fresno, C.; García-Rio, F.; Gómez-Piña, V.; Soares-Schanoski, A.; Fernández-Ruíz, I.; Jurado, T.; Kajiji, T.;
Shu, C.; Marín, E.; del Arroyo, A.G. Potent phagocytic activity with impaired antigen presentation identifying
lipopolysaccharide-tolerant human monocytes: Demonstration in isolated monocytes from cystic fibrosis
patients. J. Immunol. 2009, 182, 6494–6507. [CrossRef] [PubMed]
35. Escoll, P.; del Fresno, C.; Garcia, L.; Vallés, G.; Lendinez, M.J.; Arnalich, F.; López-Collazo, E. Rapid
up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in
monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 2003, 311, 465–472. [CrossRef]
[PubMed]
36. Foster, S.L.; Hargreaves, D.C.; Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin
modifications. Nature 2007, 447, 972–978. [CrossRef]
37. Mages, J.; Dietrich, H.; Lang, R. A genome-wide analysis of LPS tolerance in macrophages. Immunobiology
2008, 212, 723–737. [CrossRef]
38. Rajaiah, R.; Perkins, D.J.; Polumuri, S.K.; Zhao, A.; Keegan, A.D.; Vogel, S.N. Dissociation of endotoxin
tolerance and differentiation of alternatively activated macrophages. J. Immunol. 2013, 190, 4763–4772.
[CrossRef]
39. Yang, N.-B.; Ni, S.-L.; Li, S.-S.; Zhang, S.-N.; Hu, D.-P.; Lu, M.-Q. Endotoxin tolerance alleviates experimental
acute liver failure via inhibition of high mobility group box 1. Int. J. Clin. Exp. Pathol. 2015, 8, 9062.
40. Döcke, W.-D.; Randow, F.; Syrbe, U.; Krausch, D.; Asadullah, K.; Reinke, P.; Volk, H.-D.; Kox, W. Monocyte
deactivation in septic patients: Restoration by IFN-γ treatment. Nat. Med. 1997, 3, 678–681. [CrossRef]
41. Santos, S.S.; Carmo, A.M.; Brunialti, M.K.; Machado, F.R.; Azevedo, L.C.; Assunção, M.; Trevelin, S.C.;
Cunha, F.Q.; Salomao, R. Modulation of monocytes in septic patients: Preserved phagocytic activity, increased
ROS and NO generation, and decreased production of inflammatory cytokines. Intensive Care Med. Exp.
2016, 4, 5. [CrossRef] [PubMed]
42. Sáenz, J.; Izura, J.; Manrique, A.; Sala, F.; Gaminde, I. Early prognosis in severe sepsis via analyzing the
monocyte immunophenotype. Intensive Care Med. 2001, 27, 970–977. [CrossRef] [PubMed]
43. Landelle, C.; Lepape, A.; Voirin, N.; Tognet, E.; Venet, F.; Bohé, J.; Vanhems, P.; Monneret, G. Low monocyte
human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock.
Intensive Care Med. 2010, 36, 1859–1866. [CrossRef] [PubMed]
44. Kokje, V.B.; Gäbel, G.; Koole, D.; Northoff, B.H.; Holdt, L.M.; Hamming, J.F.; Lindeman, J.H. IL-6: A Janus-like
factor in abdominal aortic aneurysm disease. Atherosclerosis 2016, 251, 139–146. [CrossRef] [PubMed]
45. Englesbe, M.J.; Wu, A.H.; Clowes, A.W.; Zierler, R.E. The prevalence and natural history of aortic aneurysms
in heart and abdominal organ transplant patients. J. Vasc. Surg. 2003, 37, 27–31. [CrossRef]
46. Lindeman, J.H.; Rabelink, T.J.; van Bockel, J.H. Immunosuppression and the abdominal aortic aneurysm.
Circulation 2011, 124, e463–e465. [CrossRef]
Antioxidants 2020, 9, 896 17 of 17
47. Kobayashi, E.H.; Suzuki, T.; Funayama, R.; Nagashima, T.; Hayashi, M.; Sekine, H.; Tanaka, N.;
Moriguchi, T.; Motohashi, H.; Nakayama, K. Nrf2 suppresses macrophage inflammatory response by
blocking proinflammatory cytokine transcription. Nat. Commun. 2016, 7, 11624. [CrossRef]
48. Olsson, S.; Sundler, R. The role of lipid rafts in LPS-induced signaling in a macrophage cell line. Mol. Immunol.
2006, 43, 607–612. [CrossRef]
49. Medvedev, A.E.; Lentschat, A.; Wahl, L.M.; Golenbock, D.T.; Vogel, S.N. Dysregulation of LPS-induced
Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in
endotoxin-tolerant cells. J. Immunol. 2002, 169, 5209–5216. [CrossRef]
50. Li, C.H.; Wang, J.H.; Redmond, H.P. Bacterial lipoprotein-induced self-tolerance and cross-tolerance to LPS
are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. J. Leukoc. Biol. 2006,
79, 867–875. [CrossRef]
51. Goode, B.; Joseph, N.M.; Stevers, M.; van Ziffle, J.; Onodera, C.; Talevich, E.; Grenert, J.P.; Yeh, I.; Bastian, B.C.;
Phillips, J.J. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that
drive aberrant NF-kB pathway activation. Mod. Pathol. 2018, 31, 660. [CrossRef] [PubMed]
52. Swantek, J.L.; Tsen, M.F.; Cobb, M.H.; Thomas, J.A. IL-1 receptor-associated kinase modulates host
responsiveness to endotoxin. J. Immunol. 2000, 164, 4301–4306. [CrossRef] [PubMed]
53. Levy, B.D.; Clish, C.B.; Schmidt, B.; Gronert, K.; Serhan, C.N. Lipid mediator class switching during acute
inflammation: Signals in resolution. Nat. Immunol. 2001, 2, 612–619. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
